Neil Clark, CEO of Destiny Pharma will be attending the Bio€quity Europe 2017 meeting, to be held between the 22-23rd May in Paris, France and will be presenting information about the company on the morning of Tuesday the 23rd May. If you are attending the conference and would like to book an appointment to meet with Neil, please email us on conferences@destinypharma.com.
Destiny Board Member Elected to the Academy of Medical Sciences
Brighton, United Kingdom – 9th May, 2017 – Destiny Pharma, a clinical stage biotech company focused on the development of new anti-microbial drugs, is pleased to announce that one of its Board members, Professor David Roblin, has been elected to the Academy of Medical Sciences. David has been a director of Destiny Pharma since 2011 and the Board of Destiny congratulates him on this prestigious award.
David has recently been appointed Chief Operating Officer and President of R&D of Summit Therapeutics. Prior to this, he was Chief Operating Officer and Director of Scientific Translation at the Sir Francis Crick Institute. He was also formerly Senior Vice President and Head of R&D for Pfizer’s European sites, as well as Head of Therapy Area for Anti-Infectives at Bayer. David has a first degree in biochemistry from University College London and later qualified in medicine from St George’s Hospital.
Previous recipients include Professor Françoise Barré-Sinoussi, director of Unité de Régulation des Infections Rétrovirales, Chen Zhu, China’s Minister of Health, and Sir Andrew Witty, the former Chief Executive Officer of GlaxoSmithKline.
For full details of the announcement please visit: https://www.crick.ac.uk/news/news-archive/2017/05/08/david-roblin-and-robert-wilkinson-elected-to-the-academy-of-medical-sciences/
For further information, please visit www.destinypharma.com or contact:
Destiny Pharma Ltd
FTI Consulting
Simon Conway / Victoria Foster Mitchell / Hanna Skeppner
destinypharma@fticonsulting.com
+44 (0) 2037 271000
Notes for Editors
About the Academy of Medical Sciences
The Academy of Medical Sciences is the independent body in the UK representing the diversity of medical science. Our elected Fellows are the UK’s leading medical scientists from hospitals, academia, industry and the public service. Our mission is to advance biomedical and health research and its translation into benefits for society. We are working to secure a future in which:
- UK and global health is improved by the best research.
- The UK leads the world in biomedical and health research, and is renowned for the quality of its research outputs, talent and collaborations.
- Independent, high quality medical science advice informs the decisions that affect society.
- More people have a say in the future of health and research.
Our work focusses on four key objectives, promoting excellence, developing talented researchers, influencing research and policy and engaging patients, the public and professionals.
About Destiny Pharma Ltd
Destiny Pharma is a clinical stage biotechnology company focused on the development of novel anti-infective drugs to combat antibiotic-resistant bacteria, addressing a growing global unmet clinical need. Destiny’s patented XF drug platform represents a new approach to treat infectious disease, based on a novel molecular structure and a unique mechanism of action. XF drugs, unlike conventional antibiotics, are able to kill bacteria in any growth phase ultra-rapidly, with lower potential for the emergence of drug resistance.
The Company has completed five successful Phase I/IIa clinical trials with its lead drug, XF-73 (exeporfinium chloride). XF-73 has been awarded Qualifying Infectious Disease Product (QIDP) status and is being initially developed for the prevention of post-surgical staphylococcal infections, a potentially blockbuster indication of high unmet medical need. Destiny’s XF drug platform is being developed to prevent and treat existing and emerging “superbug” infections with a broad range of application in both primary and secondary healthcare settings.
Destiny Pharma announces appointment of new CEO
Destiny Pharma announces appointment of new CEO
Neil Clark brings extensive leadership experience in clinical stage biopharmaceutical companies, as the Company plans Phase IIb trial for lead asset in potentially blockbuster indication
Dr Bill Love, Destiny’s founder, to become Chief Scientific Officer
Brighton, United Kingdom – 13 April, 2017 – Destiny Pharma, a clinical stage biotech company focused on the development of new anti-microbial drugs, is pleased to announce the appointment of Neil Clark as Chief Executive Officer (CEO) and member of the Board of Directors, effective immediately. Concurrently, Destiny’s scientific founder and previous CEO, Dr Bill Love, has been appointed to Chief Scientific Officer (CSO).
Sir Nigel Rudd, Non-Executive Chairman of Destiny Pharma, commented:
“I am delighted to welcome Neil Clark as Chief Executive Officer of the Company. Destiny has made significant progress in the last two years, concluding in 2016 with very encouraging results from a National Institute of Health-sponsored proof-of-concept clinical study with XF-73, the lead drug from our XF drug platform. As we move forward, Neil’s extensive leadership experience in clinical stage biopharmaceutical companies will be invaluable as Destiny starts planning its first Phase IIb clinical trial. In this trial, the Company will be investigating XF-73 as a potential first-in-class drug for the prevention of post-surgical infections from all strains of Staphylococcus aureus, which we believe is a blockbuster opportunity.
“Bill Love, the founder of the Company, will continue his scientific leadership of Destiny in the newly created role of Chief Scientific Officer. As a recognised thought leader in combating the global issue of anti-microbial resistance, he will continue to focus on developing the XF platform and earlier stage projects, as the Company seeks to expand and further strengthen its already robust intellectual property position.”
On his appointment, Mr Clark added:
“I am delighted to be joining the team at Destiny at an exciting time. The resistance to antibiotics is becoming a global issue that needs to be addressed and I believe Destiny has a significant part to play. The Company has a clear focus on developing effective anti-infective drugs with low/no resistance profiles and has a potentially valuable lead asset ready to enter Phase IIb clinical development.”
Neil Clark joins Destiny from Ergomed plc, a company dedicated to the provision of specialised services to the pharmaceutical industry and the development of new drugs. Neil Clark joined Ergomed as Chief Financial Officer (CFO) in January 2009 and was CFO at its initial public offering in July 2014 until his move to be full time CEO of Ergomed’s PrimeVigilance business in January 2016. Prior to Ergomed, he was at CeNeS Pharmaceuticals plc, a company focused on developing drugs for central nervous system disorders and pain control, as CFO and subsequently CEO until its sale in 2008. Neil has spent 20 years in private and public life science companies and has a range of international experience in drug research and development, as well as licensing and partnering.
For further information, please visit www.destinypharma.com or contact:
Destiny Pharma Ltd
FTI Consulting
Simon Conway / Victoria Foster Mitchell / Hanna Skeppner
destinypharma@fticonsulting.com
+44 (0) 2037 271000
About Destiny Pharma Ltd
Destiny Pharma is a clinical stage biotechnology company focused on the development of novel anti-infective drugs to combat antibiotic-resistant bacteria, addressing a growing global unmet clinical need. Destiny’s patented XF drug platform represents a new approach to treat infectious disease, based on a novel molecular structure and a unique mechanism of action. XF drugs, unlike conventional antibiotics, are able to kill bacteria in any growth phase ultra-rapidly, with lower potential for the emergence of drug resistance.
The Company has completed five successful Phase I/IIa clinical trials with its lead drug, XF-73 (exeporfinium chloride). XF-73 has been awarded Qualifying Infectious Disease Product (QIDP) status and is being initially developed for the prevention of post-surgical staphylococcal infections, a potentially blockbuster indication of high unmet medical need. Destiny’s XF drug platform is being developed to prevent and treat existing and emerging “superbug” infections with a broad range of application in both primary and secondary healthcare settings.
Destiny Pharma to attend the 27th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) in Vienna, Austria
Destiny Pharma will be attending the 27th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), which will take place in Vienna, Austria, from 22 – 25 April 2017. Please contact us on conferences@destinypharma.com if you would like to arrange a meeting during the ECCMID meeting.
Destiny Pharma to attend Bio-Europe Meeting, Barcelona, Spain
Destiny Pharma today announced that we will be attending the 11th Annual Bio-Europe 2017 meeting, to be held between the 20-22nd March in Barcelona, Spain. If you are attending the conference and would like to book an appointment to meet with us, please email us on busdev@destinypharma.com.
For more information on the meeting, please visit the Bio-Europe page
Destiny Pharma to present at the 18th BioEquity Europe Meeting, Paris, France
Destiny Pharma today announced that they will be presenting at the BioEquity Europe 2017 meeting, to be held between the 22-23rd May in Paris, France. If you are attending the conference and would like to book an appointment to meet with us, please email us on busdev@destinypharma.com.
For more information on the meeting, please visit the BioEquity Europe page
21st Century Cures Act signed into law by President Obama
Destiny Pharma welcomes the enactment of the US 21st Century Cures Act. The provisions of the act underline the commitment of all those involved in the furtherance of policies to assist the development of novel medicines and to the removal of obstacles. Destiny is particularly pleased to see the retention of many of the specific policies to gather data on antimicrobial resistance patterns, to support antimicrobial stewardship and to provide practical drug approval pathways for tackling the most important microbial pathogens.
The Limited Population Pathway provides a route to the approval of antimicrobial products geared towards the most serious life threatening infections in difficult to study patient populations. Allowing the use of very limited patient numbers in exchange for restrictive labelling and controlled marketing of the products. This measure seeks to address the issue of unavailability of highly restricted and difficult to find patients and seeks to drive the antimicrobial drug approval process for the most serious infections.
Destiny Pharma CEO appointed to the board of GAMRIF
Dr Bill Love, CEO of Destiny Pharma, has been appointed to the expert advisory board set up by the UK government to support the Global Antimicrobial Resistance Innovation Fund (GAMRIF). Professor Dame Sally Davies, the Chief Medical Officer for England, has appointed a 12-member multi-disciplinary board who will advise how the UK can best spend an additional £50 million over the next 5 years to work with global partners to fund innovative initiatives to tackle drug resistant infections, which includes resistance to antibiotics
Wellcome Trust report on boosting development of new antimicrobial drugs
Today, the Wellcome Trust have published a report entitled “Clinical Trial Networks for Antibiotic Development: Why they’re important and how they should be developed” which is the result of work undertaken by a multi-stakeholder working group, including Destiny Pharma’s Ian Hayter, which investigated the benefits of producing a clinical trial network to boost the search for new antibiotics. The report identifies that establishing such a network could result in up to a 23% saving on clinical trial running costs and a total saving of 40 – 60% of the total cost of trials could be achieved by also using a master trial protocol and allowing multiple trials to share a single control group.
Ian Hayter, Project Director at Destiny Pharma commented “I am very encouraged by this report, which identifies potential ways to reduce the cost and time for clinical trials for new antibiotics which would boost the development of new antibacterial drugs, which are urgently needed to combat the threat of multidrug resistant bacteria.”
Destiny Pharma to attend IDWeek in New Orleans, Louisiana
Destiny Pharma will be attending IDWeek which is being held in New Orleans, Louisiana between 26-30th October. IDWeek is the combined annual meeting of the Infectious Diseases Society of America (IDSA) the Society for Healthcare Epidemiology of America (SHEA), the HIV Medicine Association (HIVMA), and the Pediatric Infectious Diseases Society (PIDS). Please contact us on conferences@destinypharma.com if you would like to arrange a meeting during IDWeek. Please note that we have slots remaining only on the 26th October.